APOEε4对Aβ免疫疗法诱导的ARIA的三个主要影响
Kate E Foley1,2, Donna M Wilcock1,2
1Stark Neurosciences Research Institute, Indiana University, Indianapolis, IN, United States.
Frontiers in aging neuroscience
|May 17, 2024
概括
基因APOEε4增加了不良影响的风险,称为粉样蛋白相关成像异常 (ARIA),来自针对粉样蛋白β (Aβ) 斑块的阿尔茨海默病 (AD) 疗法. 了解APOEε4的作用对于开发更安全的AD治疗至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 痴呆症是一种渐进的神经退行性疾病.
- 针对β-粉样蛋白 (Aβ) 斑块的疗法有希望,但会导致与粉样蛋白相关的成像异常 (ARIA).
- 包括 (ARIA-E) 和出血 (ARIA-H) 在内的ARIA具有重大风险.
研究的目的:
- 审查将APOEε4基因型与接受抗Aβ免疫治疗的患者中ARIA风险增加的机制.
- 突出APOEε4对AD治疗安全性和有效性的临床影响.
主要方法:
- 对抗Aβ免疫疗法和ARIA的临床前和临床试验数据的审查.
- 与ARIA发病率相关的遗传危险因子Apolipoprotein E ε4 (APOEε4) 的分析.
- 探索受APOEε4.4影响的拟议生物途径.
主要成果:
- APOEε4是抗Aβ免疫疗法期间发展ARIA的重要遗传风险因素.
- 假设有三个主要机制:大脑血管完整性降低,神经炎症增加和大脑粉样血管病变 (CAA) 的增加.
结论:
- APOEε4显著增加了接受AD抗粉样蛋白治疗的患者ARIA的风险.
- 需要进一步的研究来阐明APOEε4影响ARIA的确切机制.
- 了解这些机制对于缓解ARIA和扩大AD患者治疗选择至关重要.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
相关概念视频
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
